Tixagevimab/Cilgavimab

替沙格韦单抗/西加韦单抗

Report date: 2023/03/28 13:44:33

Base Information

Drug NameTixagevimab/Cilgavimab
Drug Alias NameAZD8895+AZD1061Evusheld恩适得AZD-7442AZD7442
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Leukemia, Lymphocytic, Chronic, B-CellCoronavirus Infections
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2022/03/16
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[31] 
CombinationsYes
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesVanderbilt University Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceutical Co LtdAstrazeneca Uk LtdAzienda Ospedaliera Universitaria Integrata Verona +[7] 
Inactive CompaniesMediMergent LLCMedimmune Llc
Active IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections
Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A